Adult acute myeloid leukaemia

Critical Reviews in Oncology/Hematology

Volumn 50, Issue 3, 2004, Pages 197-222

  Smith, Matthew ^a   Barnett, Michael ^a   Bassan, Renato ^b   Gatta, Gemma ^c   Tondini, Carlo ^b   Kern, Wolfgang ^d  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b OSPEDALI RIUNITI   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Acute myeloid leukaemia (AML); Diagnosis; Prognosis; Recommendations; Treatment

Indexed keywords

ACETAZOLAMIDE; ALLOPURINOL; AMINOGLYCOSIDE; ANTHRACYCLINE DERIVATIVE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIPYRETIC AGENT; BICARBONATE; CARBAPENEM; CEPHALOSPORIN; CHLORAMBUCIL; CIPROFLOXACIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; CYTARABINE TRIPHOSPHATE; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; HYDROXYUREA; ITRACONAZOLE; MELPHALAN; PENICILLIN G; POTASSIUM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE; THIOTEPA; TIOGUANINE; TREOSULFAN; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD CLOTTING DISORDER; BRAIN TOXICITY; CANCER INCIDENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; COLITIS; CONJUNCTIVITIS; CYTOCHEMISTRY; CYTOGENETICS; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; ERYTHEMA; FEVER; GASTROINTESTINAL TOXICITY; HEALTH CARE SYSTEM; HISTORY OF MEDICINE; HUMAN; IMMUNOPHENOTYPING; INFECTION; MEDICAL ASSESSMENT; MEDICAL PRACTICE; MEDICAL RESEARCH; MOLECULAR BIOLOGY; MUCOSA INFLAMMATION; MULTIDRUG RESISTANCE; NAUSEA; PREGNANCY; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; PROPHYLAXIS; QT PROLONGATION; RELAPSE; REMISSION; REVIEW; RISK FACTOR; SAMPLING; VOMITING;

ADULT; AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; NEOPLASM STAGING; PROGNOSIS; RECURRENCE; RISK FACTORS;

EID: 2942558845     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2003.11.002     Document Type: Review

References (221)

1. Ferlay J, Bray F, Pisani P, Parkin DM. Cancer incidence, mortality and prevalence worldwide, version 1.0. IARC Cancer Base No. 5. Book. Lyon: IARC Press; 2001.
2. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents, vol. VIII. IARC Scientific Publication No. 155. Lyon: International Agency for Research on Cancer; 2002.
3. Coleman MP, Babb P, Daniecki P, et al. Cancer survival trends in England and Wales, 1971-1995: deprivation and NHS region. Studies in medical and population subjects No. 61. London: The Stationary Office; 1999.
4. ENCR. European Network of Cancer Registries. Eurocim version 4.0. European Incidence Database V2.2 (1999). Lyon; 2001.
5. Berrino F, Capocaccia R, Coleman MP, Esteve J, Gatta G, Hakulinen T, et al. Survival of cancer patients in Europe: the EUROCARE-3 study. Ann Oncol 2003;14(Suppl 5).
6. Carli P.M., Coebergh J.W., Verdecchia A. EUROCARE Working Group Variation in survival of adult patients with haematological malignancies in Europe since 1978. Eur J Cancer. 34:1998;2253-2263
7. IARC. IARC ionizing radiation. Part1. X and gamma radiation and neutrons. IARC monographs on the evaluation of carcinogenic risk to humans, vol 75. Lyon: IARC Press; 2000.
8. Stewart BW, Kleihus P, editors. World cancer report. Lyon: IARC Press; 2003.
9. Savitz D.A., Calle E.E. Leukemia and occupational exposure to electromagnetic fields: review of epidemiologic surveys. J Occup Med. 29:1987;47-51
10. Theriault G., Goldberg M., Miller A.B., Armstrong B., Guenel P., Deadman J., et al. Cancer risks associated with occupational exposure to magnetic fields among electric utility workers in Ontario and Quebec, Canada, and France: 1970-1989. Am J Epidemiol. 139:1994;550-572
11. IARC. IARC: monographs on the evaluation of the carcinogenic risk of chemicals to man. Wood, leather, and some associated industries, vol. 25. Lyon: IARC Press; 1981. p. 1-97.
12. Horwitz M. The genetics of familial leukemia. Leukemia. 11:1997;1347-1359
13. Song W.J., Sullivan M.G., Legare R.D., Hutchings S., Tan X., Kufrin D., et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 23:1999;166-175
14. Hasle H., Clemmensen I.H., Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet. 355:2000;165-169
15. Taylor A.M. Chromosome instability syndromes. Best Pract Res Clin Haematol. 14:2001;631-644
16. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 33:1976;451-458
17. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 103:1985;620-625
18. Bain BJ. Leukaemia diagnosis: a guide to the FAB classification. 1st ed. London: Wolfe; 1990.
19. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 17:1999;3835-3849
20. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 100:2002;2292-2302
21. Jaffe ES. World Health Organization classification of tumours: pathology and genetics of tumours of haemopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
22. Jennings C.D., Foon K.A. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood. 90:1997;2863-2892
23. Roumier C., Eclache V., Imbert M., Davi F., Macintyre E., Garand R., et al. M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Francais d'Hematologie Cellulaire (GFHC) and the Groupe Francais de Cytogenetique Hematologique (GFCH). Blood. 101:2003;1277-1283
24. Bain B.J. Overview. Cytogenetic analysis in haematology. Best Pract Res Clin Haematol. 14:2001;463-477
25. Linenberger M.L., Hong T., Flowers D., Sievers E.L., Gooley T.A., Bennett J.M., et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood. 98:2001;988-994
26. Downing J.R. The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance. Br J Haematol. 106:1999;296-308
27. Grignani F., Fagioli M., Ferrucci P.F., Alcalay M., Pelicci P.G. The molecular genetics of acute promyelocytic leukemia. Blood Rev. 7:1993;87-93
28. Frohling S., Skelin S., Liebisch C., Scholl C., Schlenk R.F., Dohner H., et al. Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. J Clin Oncol. 20:2002;2480-2485
29. Mrozek K., Prior T.W., Edwards C., Marcucci G., Carroll A.J., Snyder P.J., et al. Comparison of cytogenetic and molecular genetic detection of t(821) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol. 19:2001;2482-2492
30. Rowe D., Cotterill S.J., Ross F.M., Bunyan D.J., Vickers S.J., Bryon J., et al. Cytogenetically cryptic AML1-ETO and CBF beta-MYH11 gene rearrangements: incidence in 412 cases of acute myeloid leukaemia. Br J Haematol. 111:2000;1051-1056
31. Thirman M.J., Gill H.J., Burnett R.C., Mbangkollo D., McCabe N.R., Kobayashi H., et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med. 329:1993;909-914
32. Stirewalt D.L., Kopecky K.J., Meshinchi S., Appelbaum F.R., Slovak M.L., Willman C.L., et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood. 97:2001;3589-3595
33. Reilly J.T. Class III receptor tyrosine kinases: role in leukaemogenesis. Br J Haematol. 116:2002;744-757
34. Beghini A., Peterlongo P., Ripamonti C.B., Larizza L., Cairoli R., Morra E., et al. C-kit mutations in core binding factor leukemias. Blood. 95:2000;726-727
35. Preudhomme C., Warot-Loze D., Roumier C., Grardel-Duflos N., Garand R., Lai J.L., et al. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood. 96:2000;2862-2869
36. Pabst T., Mueller B.U., Zhang P., Radomska H.S., Narravula S., Schnittger S., et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBP-alpha), in acute myeloid leukemia. Nat Genet. 27:2001;263-270
37. Mueller B.U., Pabst T., Osato M., Asou N., Johansen L.M., Minden M.D., et al. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood. 100:2002;998-1007
38. Osato M., Asou N., Abdalla E., Hoshino K., Yamasaki H., Okubo T., et al. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. Blood. 93:1999;1817-1824
39. Langabeer S.E., Gale R.E., Rollinson S.J., Morgan G.J., Linch D.C. Mutations of the AML1 gene in acute myeloid leukemia of FAB types M0 and M7. Genes Chromosomes Cancer. 34:2002;24-32
40. Kelly L., Clark J., Gilliland D.G. Comprehensive genotypic analysis of leukemia: clinical and therapeutic implications. Curr Opin Oncol. 14:2002;10-18
41. Alvarez S., MacGrogan D., Calasanz M.J., Nimer S.D., Jhanwar S.C. Frequent gain of chromosome 19 in megakaryoblastic leukemias detected by comparative genomic hybridization. Genes Chromosomes Cancer. 32:2001;285-293
42. Golub T.R., Slonim D.K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J.P., et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 286:1999;531-537
43. Schoch C., Kohlmann A., Schnittger S., Brors B., Dugas M., Mergenthaler S., et al. Acute myeloid leukaemias with reciprocal rearrangements can be distinguished by specific gene expression prolifes. Proc Natl Acad Sci USA. 99:2002;10008-10013
44. Mirro J., Zipf T.F., Pui C.H., Kitchingman G., Williams D., Melvin S., et al. Acute mixed lineage leukemia: clinicopathologic correlations and prognostic significance. Blood. 66:1985;1115-1123
45. BCSH. The role of cytology, cytochemistry, immunophenotyping and cytogenetic analysis in the diagnosis of haematological neoplasms. General Haematology Task Force of the BCSH. Clin Lab Haematol 1996;18:231-6.
46. BCSH. Immunophenotyping in the diagnosis of acute leukaemias. General Haematology Task Force of BCSH. J Clin Pathol 1994;47:777-81.
47. Bene M.C., Castoldi G., Knapp W., Ludwig W.D., Matutes E., Orfao A., et al. European Group for the Immunological Characterization of Leukemias (EGIL) Proposals for the immunological classification of acute leukemias. Leukemia. 9:1995;1783-1786
48. Juneja S., Trute L., Westerman D., Venter D., Seymour J.F., Prince H.M., et al. Paraffin section immunotyping of leukaemias. Br J Haematol. 109:2000;267-271
49. Swirsky D.M., Richards S.J. Laboratory diagnosis of acute myeloid leukaemia. Best Pract Res Clin Haematol. 14:2001;1-17
50. Kern W., Haferlach T., Schoch C., Loffler H., Gassmann W., Heinecke A., et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 trial. Blood. 101:2003;64-70
51. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., et al. The Medical Research Council Adult and Children's Leukaemia Working Parties The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. Blood. 92:1998;2322-2333
52. Grimwade D., Walker H., Harrison G., Oliver F., Chatters S., Harrison C.J., et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 98:2001;1312-1320
53. Slovak M.L., Kopecky K.J., Cassileth P.A., Harrington D.H., Theil K.S., Mohamed A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 96:2000;4075-4083
54. Haferlach T., Schoch C., Loffler H., Gassmann W., Kern W., Schnittger S., et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol. 21:2003;256-265
55. Baer M.R., Stewart C.C., Lawrence D., Arthur D.C., Byrd J.C., Davey F.R., et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(821)(q22q22). Blood. 90:1997;1643-1648
56. Byrd J.C., Weiss R.B., Arthur D.C., Lawrence D., Baer M.R., Davey F., et al. Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. J Clin Oncol. 15:1997;466-475
57. Nguyen S., Leblanc T., Fenaux P., Witz F., Blaise D., Pigneux A., et al. A white blood cell index as the main prognostic factor in t(821) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood. 99:2002;3517-3523
58. Schoch C., Haase D., Haferlach T., Gudat H., Buchner T., Freund M., et al. Fifty-one patients with acute myeloid leukemia and translocation t(821)(q22q22): an additional deletion in 9q is an adverse prognostic factor. Leukemia. 10:1996;1288-1295
59. Burnett A.K., Grimwade D., Solomon E., Wheatley K., Goldstone A.H. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood. 93:1999;4131-4143
60. Marie J.P. Drug resistance in hematologic malignancies. Curr Opin Oncol. 13:2001;463-469
61. Beck W.T., Grogan T.M., Willman C.L., Cordon-Cardo C., Parham D.M., Kuttesch J.F., et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res. 56:1996;3010-3020
62. Marie J.P., Huet S., Faussat A.M., Perrot J.Y., Chevillard S., Barbu V., et al. French Network of the Drug Resistance Intergroup, and Drug Resistance Network of Assistance Publique-Hopitaux de Paris Multicentric evaluation of the MDR phenotype in leukemia. Leukemia. 11:1997;1086-1094
63. Campos L., Guyotat D., Archimbaud E., Calmard-Oriol P., Tsuruo T., Troncy J., et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood. 79:1992;473-476
64. Leith C.P., Kopecky K.J., Godwin J., McConnell T., Slovak M.L., Chen I.M., et al. Southwest Oncology Group study Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. Blood. 89:1997;3323-3329
65. Leith C.P., Kopecky K.J., Chen I.M., Eijdems L., Slovak M.L., McConnell T.S., et al. Southwest Oncology Group Study Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. Blood. 94:1999;1086-1099
66. Laupeze B., Amiot L., Drenou B., Bernard M., Branger B., Grosset J.M., et al. High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival. Br J Haematol. 116:2002;834-838
67. Filipits M., Pohl G., Stranzl T., Suchomel R.W., Scheper R.J., Jager U., et al. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood. 91:1998;1508-1513
68. Tsuji K., Motoji T., Sugawara I., Shiozaki H., Wang Y.H., Motomura S., et al. Significance of lung resistance-related protein in the clinical outcome of acute leukaemic patients with reference to P-glycoprotein. Br J Haematol. 110:2000;370-378
69. Sargent J.M., Williamson C.J., Maliepaard M., Elgie A.W., Scheper R.J., Taylor C.G. Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. Br J Haematol. 115:2001;257-262
70. van der Kolk D.M., Vellenga E., Scheffer G.L., Muller M., Bates S.E., Scheper R.J., et al. Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood. 99:2002;3763-3770
71. Legrand O., Simonin G., Perrot J.Y., Zittoun R., Marie J.P. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood. 91:1998;4480-4488
72. Karaszi E., Jakab K., Homolya L., Szakacs G., Hollo Z., Telek B., et al. Calcein assay for multidrug resistance reliably predicts therapy response and survival rate in acute myeloid leukaemia. Br J Haematol. 112:2001;308-314
73. Yokota S., Kiyoi H., Nakao M., Iwai T., Misawa S., Okuda T., et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia. 11:1997;1605-1609
74. Gilliland D.G., Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood. 100:2002;1532-1542
75. Abu-Duhier F.M., Goodeve A.C., Wilson G.A., Gari M.A., Peake I.R., Rees D.C., et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol. 111:2000;190-195
76. Kottaridis P.D., Gale R.E., Frew M.E., Harrison G., Langabeer S.E., Belton A.A., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 98:2001;1752-1759
77. Whitman S.P., Archer K.J., Feng L., Baldus C., Becknell B., Carlson B.D., et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 61:2001;7233-7239
78. Thiede C., Steudel C., Mohr B., Schaich M., Schakel U., Platzbecker U., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 99:2002;4326-4335
79. Schnittger S., Schoch C., Dugas M., Kern W., Staib P., Wuchter C., et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 100:2002;59-66
80. Kottaridis P.D., Gale R.E., Langabeer S.E., Frew M.E., Bowen D.T., Linch D.C. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood. 100:2002;2393-2398
81. Shih L.Y., Huang C.F., Wu J.H., Lin T.L., Dunn P., Wang P.N., et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood. 100:2002;2387-2392
82. Yamamoto Y., Kiyoi H., Nakano Y., Suzuki R., Kodera Y., Miyawaki S., et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 97:2001;2434-2439
83. Campos L., Rouault J.P., Sabido O., Oriol P., Roubi N., Vasselon C., et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 81:1993;3091-3096
84. Ong Y.L., McMullin M.F., Bailie K.E., Lappin T.R., Jones F.G., Irvine A.E. High bax expression is a good prognostic indicator in acute myeloid leukaemia. Br J Haematol. 111:2000;182-189
85. Braess J., Jahns-Streubel G., Schoch C., Haase D., Haferlach T., Fiegl M., et al. Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia. Br J Haematol. 113:2001;975-982
86. Galmarini C.M., Graham K., Thomas X., Calvo F., Rousselot P., El Jafaari A., et al. Expression of high Km 5′-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. Blood. 98:2001;1922-1926
87. Voso M.T., D'Alo' F., Putzulu R., Mele L., Scardocci A., Chiusolo P., et al. Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. Blood. 100:2002;2703-2707
88. Preudhomme C., Sagot C., Boissel N., Cayuela J.M., Tigaud I., de Botton S., et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood. 100:2002;2717-2723
89. van Waalwijk V., Erpelinck C., Meijer J., van Oosterhoud S., van Putten W.L., Valk P.J., et al. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J. 4:2003;31-40
90. van Waalwijk van Doorn B, Erpelinck C, van Putten WL, Valk PJ, van der Poel-van de Luytgaarde S, Hack R, et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 2003;101:837-45.
91. Sperr W.R., Jordan J.H., Baghestanian M., Kiener H.P., Samorapoompichit P., Semper H., et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood. 98:2001;2200-2209
92. Verstovsek S., Kantarjian H., Aguayo A., Manshouri T., Freireich E., Keating M., et al. Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome. Br J Haematol. 114:2001;290-295
93. Kappelmayer J., Kiss A., Karaszi E., Veszpremi A., Jako J., Kiss C. Identification of P-selectin glycoprotein ligand-1 as a useful marker in acute myeloid leukaemias. Br J Haematol. 115:2001;903-909
94. Oliver L., Vavasseur F., Mahe B., Perrin P., Harousseau J.L., Meflah K., et al. Assessment of caspase activity as a possible prognostic factor in acute myeloid leukaemia. Br J Haematol. 118:2002;434-437
95. Niitsu N., Okabe-Kado J., Nakayama M., Wakimoto N., Sakashita A., Maseki N., et al. Plasma levels of the differentiation inhibitory factor nm23-H1 protein and their clinical implications in acute myelogenous leukemia. Blood. 96:2000;1080-1086
96. Adida C., Recher C., Raffoux E., Daniel M.T., Taksin A.L., Rousselot P., et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol. 111:2000;196-203
97. Flombaum C.D. Metabolic emergencies in the cancer patient. Semin Oncol. 27:2000;322-334
98. Goldman S.C., Holcenberg J.S., Finklestein J.Z., Hutchinson R., Kreissman S., Johnson F.L., et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 97:2001;2998-3003
99. Navolanic P.M., Pui C.H., Larson R.A., Bishop M.R., Pearce T.E., Cairo M.S., et al. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia. 17:2003;499-514
100. Cornely O.A., Ullmann A.J., Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood. 101:2003;3365-3372
101. Vamvakas E.C., Pineda A.A. Meta-analysis of clinical studies of the efficacy of granulocyte transfusions in the treatment of bacterial sepsis. J Clin Apheresis. 11:1996;1-9
102. Barbui T, Finazzi G, Falanga A. Management of bleeding and thrombosis in acute leukaemia and chronic myeloproliferative disorders. In: Henderson ES, Lister TA, Greaves MF, editors. Leukaemia. 7th ed. Philadelphia: Saunders; 2002. p. 363-82.
103. Murphy M.F., Brozovic B., Murphy W., Ouwehand W., Waters A.H. British Committee for Standards in Haematology, Working Party of the Blood Transfusion Task Force Guidelines for platelet transfusions. Transfus Med. 2:1992;311-318
104. Beutler E. Platelet transfusions: the 20, 000 μl trigger. Blood. 81:1993;1411-1413
105. Callow C.R., Swindell R., Randall W., Chopra R. The frequency of bleeding complications in patients with haematological malignancy following the introduction of a stringent prophylactic platelet transfusion policy. Br J Haematol. 118:2002;677-682
106. Goldberg M.A., Ginsburg D., Mayer R.J., Stone R.M., Maguire M., Rosenthal D.S., et al. Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia? Blood. 69:1987;187-191
107. Burnett A.K. Treatment of acute myeloid leukaemia in younger patients. Best Pract Res Clin Haematol. 14:2001;95-118
108. Yates J., Glidewell O., Wiernik P., Cooper M.R., Steinberg D., Dosik H., et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood. 60:1982;454-462
109. AMLCG. AML Collaborative Group. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Br J Haematol 1998;103:100-9.
110. Berman E., Heller G., Santorsa J., McKenzie S., Gee T., Kempin S., et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 77:1991;1666-1674
111. Vogler W.R., Velez-Garcia E., Weiner R.S., Flaum M.A., Bartolucci A.A., Omura G.A., et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol. 10:1992;1103-1111
112. Wiernik P.H., Banks P.L., Case D.C.J., Arlin Z.A., Periman P.O., Todd M.B., et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 79:1992;313-319
113. Dillman R.O., Davis R.B., Green M.R., Weiss R.B., Gottlieb A.J., Caplan S., et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood. 78:1991;2520-2526
114. Burnett AK, Wheatley K, Goldstone AH, Prentice A. Attempts to improve induction treatment in AML patients under 60 years: the impact of mitoxantrone; ARA-C dose and retinoid acid: results of MRC AML 12. Hematol J 2002;3(Suppl 1):159.
115. Stasi R., Venditti A., Del Poeta G., Aronica G., Abruzzese E., Pisani F., et al. High-dose chemotherapy in adult acute myeloid leukemia: rationale and results. Leuk Res. 20:1996;535-549
116. Bishop J.F., Matthews J.P., Young G.A., Szer J., Gillett A., Joshua D., et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 87:1996;1710-1717
117. Weick J.K., Kopecky K.J., Appelbaum F.R., Head D.R., Kingsbury L.L., Balcerzak S.P., et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 88:1996;2841-2851
118. Buchner T., Hiddemann W., Wormann B., Loffler H., Gassmann W., Haferlach T., et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine. A randomized trial by the German AML Cooperative Group. Blood. 93:1999;4116-4124
119. Bishop J.F., Lowenthal R.M., Joshua D., Matthews J.P., Todd D., Cobcroft R., et al. Australian Leukemia Study Group Etoposide in acute nonlymphocytic leukemia. Blood. 75:1990;27-32
120. Hann I.M., Stevens R.F., Goldstone A.H., Rees J.K., Wheatley K., Gray R.G., et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood. 89:1997;2311-2318
121. Stevens R.F., Hann I.M., Wheatley K., Gray R.G. MRC Childhood Leukaemia Working Party Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. Br J Haematol. 101:1998;130-140
122. Miyawaki S., Tanimoto M., Kobayashi T., Minami S., Tamura J., Omoto E., et al. Japan Adult Leukemia Study Group No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Int J Hematol. 70:1999;97-104
123. Keating MJ, Estey E, O'Brien S, Kantarjian H, Robertson LE, Plunkett W. Clinical experience with fludarabine in leukaemia. Drugs 1994;47(Suppl 6):39-49.
124. Ozer H., Armitage J.O., Bennett C.L., Crawford J., Demetri G.D., Pizzo P.A., et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based. J Clin Oncol. 18:2000;3558-3585
125. ESMO. ESMO recommendations for the application of haematopoietic growth factors (hGFs). Ann Oncol 2001;12:1219-20.
126. Wheatley K., Burnett A.K., Gibson B., Goldstone A.H., Webb D.K., Prentice A., et al. Optimising consolidation therapy: four versus five courses SCT versus chemotherapy - preliminary results of MRC AML 12. Hematol J. 3(S1):2002;159
127. Mayer R.J., Davis R.B., Schiffer C.A., Berg D.T., Powell B.L., Schulman P., et al. Cancer and Leukemia Group B Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 331:1994;896-903
128. Byrd J.C., Dodge R.K., Carroll A., Baer M.R., Edwards C., Stamberg J., et al. Patients with t(821)(q22q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 17:1999;3767-3775
129. Cassileth P.A., Lynch E., Hines J.D., Oken M.M., Mazza J.J., Bennett J.M., et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood. 79:1992;1924-1930
130. Gorin N.C. Autologous stem cell transplantation in acute myelocytic leukemia. Blood. 92:1998;1073-1090
131. Gorin N.C. Autologous stem cell transplantation for adult acute leukemia. Curr Opin Oncol. 14:2002;152-159
132. Zittoun R.A., Mandelli F., Willemze R., de Witte T., Labar B., Resegotti L., et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 332:1995;217-223
133. Harousseau J.L., Cahn J.Y., Pignon B., Witz F., Milpied N., Delain M., et al. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM) Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood. 90:1997;2978-2986
134. Burnett A.K., Goldstone A.H., Stevens R.M., Hann I.M., Rees J.K., Gray R.G., et al. UK Medical Research Council Adult and Children's Leukaemia Working Parties Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet. 351:1998;700-708
135. Cassileth P.A., Harrington D.P., Appelbaum F.R., Lazarus H.M., Rowe J.M., Paietta E., et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 339:1998;1649-1656
136. Burnett A.K., Wheatley K., Goldstone A.H., Stevens R.F., Hann I.M., Rees J.H., et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol. 118:2002;385-400
137. Appelbaum F.R., Fisher L.D., Thomas E.D. Chemotherapy v marrow transplantation for adults with acute nonlymphocytic leukemia: a five year follow-up. Blood. 72:1988;179-184
138. McGlave P.B., Haake R.J., Bostrom B.C., Brunning R., Hurd D.D., Kim T.H., et al. Allogeneic bone marrow transplantation for acute nonlymphocytic leukemia in first remission. Blood. 72:1988;1512-1517
139. Schiller G.J., Nimer S.D., Territo M.C., Ho W.G., Champlin R.E., Gajewski J.L., et al. Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission. J Clin Oncol. 10:1992;41-46
140. Chen A.R., Alonzo T.A., Woods W.G., Arceci R.J. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? An American view. Br J Haematol. 118:2002;378-384
141. Creutzig U., Reinhardt D. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? A European view. Br J Haematol. 118:2002;365-377
142. Wheatley K. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? A statistician's view. Br J Haematol. 118:2002;351-356
143. Messner H.A. Long-term outcome of allogeneic transplants in acute myeloid leukemia. Leukemia. 16:2002;751-752
144. Burnett A.K., Kell J. High dose cytarabine or transplantation for consolidation of younger patients with acute myeloid leukemia. Curr Opin Oncol. 12:2000;110-115
145. Burnett A.K. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? An adult treater's view. Br J Haematol. 118:2002;357-364
146. Ferrant A., Labopin M., Frassoni F., Prentice H.G., Cahn J.Y., Blaise D., et al. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European
147. Bertz H., Potthoff K., Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol. 21:2003;1480-1484
148. Schoch C., Haferlach T., Haase D., Fonatsch C., Loffler H., Schlegelberger B., et al. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol. 112:2001;118-126
149. Webb D.K. Management of relapsed acute myeloid leukaemia. Br J Haematol. 106:1999;851-859
150. Jackson G., Taylor P., Smith G.M., Marcus R., Smith A., Chu P., et al. A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol. 112:2001;127-137
151. Kern W., Schleyer E., Braess J., Wittmer E., Ohnesorge J., Unterhalt M., et al. Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias. Ann Hematol. 80:2001;334-339
152. Liu Y.J., Wheatley K., Rees J.K., Burnett A.K. Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br J Haematol. 113:2001;713-726
153. Dorr R., Karanes C., Spier C., Grogan T., Greer J., Moore J., et al. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. J Clin Oncol. 19:2001;1589-1599
154. Baer M.R., George S.L., Dodge R.K., O'Loughlin K.L., Minderman H., Caligiuri M.A., et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 100:2002;1224-1232
155. Avvisati G., Lo C.F., Diverio D., Falda M., Ferrara F., Lazzarino M., et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood. 88:1996;1390-1398
156. Avvisati G., Petti M.C., Lo-Coco F., Vegna M.L., Amadori S., Baccarani M., et al. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood. 100:2002;3141-3146
157. Sanz M.A., Martin G., Rayon C., Esteve J., Gonzalez M., Diaz-Mediavilla J., et al. PETHEMA group A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. Blood. 94:1999;3015-3021
158. Sanz M.A., Lo C.F., Martin G., Avvisati G., Rayon C., Barbui T., et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 96:2000;1247-1253
159. Lo Coco F., Nervi C., Avvisati G., Mandelli F. Acute promyelocytic leukemia: a curable disease. Leukemia. 12:1998;1866-1880
160. Tallman M.S., Andersen J.W., Schiffer C.A., Appelbaum F.R., Feusner J.H., Ogden A., et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 337:1997;1021-1028
161. Tallman M.S., Andersen J.W., Schiffer C.A., Appelbaum F.R., Feusner J.H., Woods W.G., et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 100:2002;4298-4302
162. de Botton S., Dombret H., Sanz M., Miguel J.S., Caillot D., Zittoun R., et al. The European APL Group Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. Blood. 92:1998;2712-2718
163. Tallman M.S., Andersen J.W., Schiffer C.A., Appelbaum F.R., Feusner J.H., Ogden A., et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood. 95:2000;90-95
164. Grimwade D. The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease. Br J Haematol. 106:1999;591-613
165. Grimwade D., Lo C.F. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia. 16:2002;1959-1973
166. Lo Coco F., Diverio D., Falini B., Biondi A., Nervi C., Pelicci P.G. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood. 94:1999;12-22
167. Soignet S.L., Maslak P., Wang Z.G., Jhanwar S., Calleja E., Dardashti L.J., et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 339:1998;1341-1348
168. Soignet S.L., Frankel S.R., Douer D., Tallman M.S., Kantarjian H., Calleja E., et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 19:2001;3852-3860
169. Douer D. Advances in the treatment of relapsed acute promyelocytic leukemia. Acta Haematol. 107:2002;1-17
170. Hiddemann W., Kern W., Schoch C., Fonatsch C., Heinecke A., Wormann B., et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol. 17:1999;3569-3576
171. Sekeres M.A., Stone R.M. The challenge of acute myeloid leukemia in older patients. Curr Opin Oncol. 14:2002;24-30
172. Taylor P.R., Reid M.M., Stark A.N., Bown N., Hamilton P.J., Proctor S.J. De novo acute myeloid leukaemia in patients over 55 years-old: a population-based study of incidence. Leukemia. 9:1995;231-237
173. Goldstone A.H., Burnett A.K., Wheatley K., Smith A.G., Hutchinson R.M., Clark R.E. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 98:2001;1302-1311
174. Estey E.H. How I treat older patients with AML. Blood. 96:2000;1670-1673
175. Anderson J.E., Kopecky K.J., Willman C.L., Head D., O'Donnell M.R., Luthardt F.W., et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood. 100:2002;3869-3876
176. Caligiuri M.A., Mayer R.J. Pregnancy and leukemia. Semin Oncol. 16:1989;388-396
177. Reynoso E.E., Shepherd F.A., Messner H.A., Farquharson H.A., Garvey M.B., Baker M.A. Acute leukemia during pregnancy: the Toronto Leukemia Study Group experience with long-term follow-up of children exposed in utero to chemotherapeutic agents. J Clin Oncol. 5:1987;1098-1106
178. -1) currently needed to declare CR in AML. Leuk Res. 27:2003;475-479
179. Cheson B.D., Cassileth P.A., Head D.R., Schiffer C.A., Bennett J.M., Bloomfield C.D., et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 8:1990;813-819
180. Campana D., Pui C.H. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood. 85:1995;1416-1434
181. Yin J.A., Tobal K. Detection of minimal residual disease in acute myeloid leukaemia: methodologies. Br J Haematol. 106:1999;578-590
182. Yin J.A., Grimwade D. Minimal residual disease evaluation in acute myeloid leukaemia. Lancet. 360:2002;160-162
183. Gallagher R.E., Yeap B.Y., Bi W., Livak K.J., Beaubier N., Rao S., et al. Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood. 101:2003;2521-2528
184. Buonamici S., Ottaviani E., Testoni N., Montefusco V., Visani G., Bonifazi F., et al. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood. 99:2002;443-449
185. van der Reijden B.A., Simons A., Luiten E., van der Poel S.C., Hogenbirk P.E., Tonnissen E., et al. Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB-MYH11 gene fusion. Br J Haematol. 118:2002;411-418
186. Ogawa H., Tamaki H., Ikegame K., Soma T., Kawakami M., Tsuboi A., et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood. 101:2003;1698-1704
187. Venditti A., Buccisano F., Del Poeta G., Maurillo L., Tamburini A., Cox C., et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood. 96:2000;3948-3952
188. Giles F.J. Novel agents for the therapy of acute leukemia. Curr Opin Oncol. 14:2002;3-9
189. Appelbaum F.R. New targets for therapy in acute myeloid leukemia. Leukemia. 17:2003;492-495
190. Seiter K., Feldman E.J., Halicka H.D., Traganos F., Darzynkiewicz Z., Lake D., et al. Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia. J Clin Oncol. 15:1997;44-51
191. Apostolidou E., Estey E., Cortes J., Garcia-Manero G., Faderl S., Thomas D., et al. Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia. Leuk Res. 27:2003;301-304
192. Kantarjian H.M., Gandhi V., Kozuch P., Faderl S., Giles F., Cortes J., et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. 21:2003;1167-1173
193. Arceci R.J. Can multidrug resistance mechanisms be modified? Br J Haematol. 110:2000;285-291
194. Larson R.A. Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia? Leukemia. 17:2003;488-491
195. Marcucci G., Byrd J.C., Dai G., Klisovic M.I., Kourlas P.J., Young D.C., et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood. 101:2003;425-432
196. Kelly L.M., Yu J.C., Boulton C.L., Apatira M., Li J., Sullivan C.M., et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell. 1:2002;421-432
197. Levis M., Allebach J., Tse K.F., Zheng R., Baldwin B.R., Smith B.D., et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 99:2002;3885-3891
198. Weisberg E., Boulton C., Kelly L.M., Manley P., Fabbro D., Meyer T., et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 1:2002;433-443
199. Yee K.W., O'Farrell A.M., Smolich B.D., Cherrington J.M., McMahon G., Wait C.L., et al. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood. 100:2002;2941-2949
200. Dancey J., Sausville E.A. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov. 2:2003;296-313
201. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., Kelly W.K., et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 1:2001;194-202
202. Karp J.E., Lancet J.E., Kaufmann S.H., End D.W., Wright J.J., Bol K., et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 97:2001;3361-3369
203. Frankel A.E., Sievers E.L., Scheinberg D.A. Cell surface receptor-targeted therapy of acute myeloid leukemia: a review. Cancer Biother Radiopharm. 15:2000;459-476
204. Tallman M.S. Antibody-based strategies for the treatment of acutre myeloid leukaemia. Clin Lymphoma. 2(Suppl 1):2002;S1-S39
205. Feldman E., Kalaycio M., Weiner G., Frankel S., Schulman P., Schwartzberg L., et al. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia. 17:2003;314-318
206. Illidge T.M., Johnson P.W. The emerging role of radioimmunotherapy in haematological malignancies. Br J Haematol. 108:2000;679-688
207. Jurcic J.G. Antibody therapy of acute myelogenous leukemia. Cancer Biother Radiopharm. 15:2000;319-326
208. Jurcic J.G., Larson S.M., Sgouros G., McDevitt M.R., Finn R.D., Divgi C.R., et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood. 100:2002;1233-1239
209. van Der Velden V.H., Marvelde J.G., Hoogeveen P.G., Bernstein I.D., Houtsmuller A.B., Berger M.S., et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood. 97:2001;3197-3204
210. Larson R.A., Boogaerts M., Estey E., Karanes C., Stadtmauer E.A., Sievers E.L., et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 16:2002;1627-1636
211. ®) combined with chemotherapy regimens in acute myeloid leukemia. Clin Lymphoma 2002;2(Suppl 1):S24-8.
212. Barrett J., Childs R. Non-myeloablative stem cell transplants. Br J Haematol. 111:2000;6-17
213. Champlin R., Khouri I., Shimoni A., Gajewski J., Kornblau S., Molldrem J., et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol. 111:2000;18-29
214. Storb R. Mixed allogeneic chimerism and graft-versus-leukemia effects in acute myeloid leukemia. Leukemia. 16:2002;753-754
215. Shan K., Lincoff A.M., Young J.B. Anthracycline-induced cardiotoxicity. Ann Intern Med. 125:1996;47-58
216. Anderlini P., Benjamin R.S., Wong F.C., Kantarjian H.M., Andreeff M., Kornblau S.M., et al. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol. 13:1995;2827-2834
217. Brennan B.M., Shalet S.M. Endocrine late effects after bone marrow transplant. Br J Haematol. 118:2002;58-66
218. Socie G., Salooja N., Cohen A., Rovelli A., Carreras E., Locasciulli A., et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood. 101:2003;3373-3385
219. de Lima M., Strom S.S., Keating M., Kantarjian H., Pierce S., O'Brien S., et al. Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work. Blood. 90:1997;4719-4724
220. Deeg H.J., Socie G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood. 91:1998;1833-1844
221. Socie G., Stone J.V., Wingard J.R., Weisdorf D., Henslee-Downey P.J., Bredeson C., et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med. 341:1999;14-21